Download MendeleyDiscovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies.
Lampe, J.W., Alford, J.S., Boriak-Sjodin, P.A., Brach, D., Cosmopoulos, K., Duncan, K.W., Eckley, S.T., Foley, M.A., Harvey, D.M., Motwani, V., Munchhof, M.J., Raimondi, A., Riera, T.V., Tang, C., Thomenius, M.J., Totman, J., Farrow, N.A.(2021) ACS Med Chem Lett 12: 1539-1545
- PubMed: 34671445
- DOI: https://doi.org/10.1021/acsmedchemlett.1c00272
- Primary Citation of Related Structures:
7LZB, 7LZD, 7LZF - PubMed Abstract:
SET domain-containing protein 2 (SETD2), a histone methyltransferase, has been identified as a target of interest in certain hematological malignancies, including multiple myeloma. This account details the discovery of EPZ-719 , a novel and potent SETD2 inhibitor with a high selectivity over other histone methyltransferases. A screening campaign of the Epizyme proprietary histone methyltransferase-biased library identified potential leads based on a 2-amidoindole core. Structure-based drug design (SBDD) and drug metabolism/pharmacokinetics (DMPK) optimization resulted in EPZ-719 , an attractive tool compound for the interrogation of SETD2 biology that enables in vivo target validation studies.
Organizational Affiliation:
Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States.
